ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

China's Sinovac starts production of COVID-19 vaccine candidate

Compatriot CanSino also rushes for mass output as clinical trials continue

Students in Indonesia wear protective face masks. Sinovac has agreed to supply 40 million doses to an Indonesian state-owned company.   © Reuters

DALIAN, China -- Sinovac Biotech has begun manufacturing a coronavirus vaccine candidate on a pilot basis, as China shifts toward the mass production stage in the global immunization race.

Production has started at a new plant in Beijing with an annual capacity of roughly 300 million doses. Sinovac has agreed to supply 40 million doses to Bio Farma, an Indonesian state-owned company, between November and March. Sinovac started building the factory in late March and finished the project in July.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more